Portfolio
Portfolio

Allecra Therapeutics

Novel treatments to combat multi drug-resistant bacterial infections.

Allecra Therapeutics, a clinical stage biopharmaceutical company, was established in 2013 and is dedicated to the development of novel treatments to combat multi drug-resistant bacterial infections. Allecra has a novel β-lactamase inhibitor in Phase 2 clinical development. By inhibiting β-lactamases Allecra’s new medicine directly tackles emerging resistance mechanisms of certain hard-to-treat bacteria. The product is currently in a phase II clinical trial.

  • CEO Nicholas Benedict
  • Industry Biotech